Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Dissecting tumor heterogeneity in colorectal cancer: uncovering the role of BCL2L1(+) cells through single-cell analysis.
PMID 41958675 · PMC13056825 · Frontiers in immunology · 2026 · 8 claims · 8 setups
scRNA-seq identifies five CRC tumor cell subtypes, with the C4 BCL2L1+ subtype predominantly enriched in liver metastases and showing enhanced proliferation, metabolic reprogramming, and anti-apoptotic activity
-
Full-text index only
SARS-CoV-2 infection during the first trimester leads to profound immune dysregulation at the maternal-fetal interface despite limited virus detection in placental tissues.
PMID 41974725 · PMC13249863 · Nature communications · 2026 · 8 claims · 8 setups
SARS-CoV-2 rarely infects villous and decidual placental tissues in the first trimester despite maternal infection
-
Full-text index only
Single-cell analysis highlights the role of CD4(+) IFN-I-related T cells in Behcet's uveitis during Interferonα-2a therapy.
PMID 42021381 · PMC13238117 · Biology direct · 2026 · 6 claims · 8 setups
CD4+ IFN-I-related T cells are significantly decreased in active BD patients and restored after IFNα-2a therapy
-
Has reproduction · 71
Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events.
PMID 41254329 · PMC12627558 · Communications medicine · 2025 · 7 claims · 6 setups
Blood of steroid non-responders shows elevated Tc1/Tc17 CD8+ T cells and Th1/Th17-associated interleukins before steroid initiation
-
Full-text index only
MAZ-mediated tumor progression and immune evasion in hormone receptor-positive breast cancer: Targeting tumor microenvironment and PCLAF+ subtype-specific therapy.
PMID 39805182 · PMC11780959 · Translational oncology · 2025 · 6 claims · 8 setups
A C3 PCLAF+ tumor cell subtype identified by scRNA-seq shows high proliferation/differentiation potential and is linked to aggressive tumor behavior and poor prognosis in HR+BC